130 related articles for article (PubMed ID: 26043762)
1. Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.
Brankley SM; Halling KC; Jenkins SM; Timmer MR; Iyer PG; Smyrk TC; Barr Fritcher EG; Voss JS; Kipp BR; Campion MB; Lutzke LS; Minot DM; Wang KK
Dis Esophagus; 2016 Aug; 29(6):513-9. PubMed ID: 26043762
[TBL] [Abstract][Full Text] [Related]
2. A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus.
Fritcher EG; Brankley SM; Kipp BR; Voss JS; Campion MB; Morrison LE; Legator MS; Lutzke LS; Wang KK; Sebo TJ; Halling KC
Hum Pathol; 2008 Aug; 39(8):1128-35. PubMed ID: 18602665
[TBL] [Abstract][Full Text] [Related]
3. A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus.
Poneros JM; Faye AS; Barr Fritcher EG; Sen A; Anandasabapathy S; Bresalier RS; Marcon N; Turgeon DK; Appelman H; Normolle D; Morrison LE; Brenner DE; Halling KC
Dig Dis Sci; 2017 May; 62(5):1216-1222. PubMed ID: 28265829
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
5. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
6. Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade.
Geppert CI; Rümmele P; Sarbia M; Langer R; Feith M; Morrison L; Pestova E; Schneider-Stock R; Hartmann A; Rau TT
Br J Cancer; 2014 Jun; 110(12):2985-95. PubMed ID: 24853183
[TBL] [Abstract][Full Text] [Related]
7. The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus.
Brankley SM; Wang KK; Harwood AR; Miller DV; Legator MS; Lutzke LS; Kipp BR; Morrison LE; Halling KC
J Mol Diagn; 2006 May; 8(2):260-7. PubMed ID: 16645214
[TBL] [Abstract][Full Text] [Related]
8. Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers.
Timmer MR; Brankley SM; Gorospe EC; Sun G; Lutzke LS; Iyer PG; Halling KC; Krishnadath KK; Wang KK
Gastrointest Endosc; 2014 Dec; 80(6):984-91. PubMed ID: 25085335
[TBL] [Abstract][Full Text] [Related]
9. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.
Weston AP; Badr AS; Hassanein RS
Am J Gastroenterol; 1999 Dec; 94(12):3413-9. PubMed ID: 10606296
[TBL] [Abstract][Full Text] [Related]
10. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus].
Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M
Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407
[TBL] [Abstract][Full Text] [Related]
11. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
12. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
Stachler MD; Camarda ND; Deitrick C; Kim A; Agoston AT; Odze RD; Hornick JL; Nag A; Thorner AR; Ducar M; Noffsinger A; Lash RH; Redston M; Carter SL; Davison JM; Bass AJ
Gastroenterology; 2018 Jul; 155(1):156-167. PubMed ID: 29608884
[TBL] [Abstract][Full Text] [Related]
13. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
[TBL] [Abstract][Full Text] [Related]
14. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens.
Fahmy M; Skacel M; Gramlich TL; Brainard JA; Rice TW; Goldblum JR; Connor JT; Casey G; Legator MS; Tubbs RR; Falk GW
Mod Pathol; 2004 May; 17(5):588-96. PubMed ID: 15017433
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
Whitson MJ; Falk GW
Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
[TBL] [Abstract][Full Text] [Related]
17. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
18. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
19. Generation of locus-specific probes for interphase fluorescence in situ hybridisation--application in Barrett's esophagus.
Doak SH; Saidely D; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
Exp Mol Pathol; 2004 Aug; 77(1):26-33. PubMed ID: 15215047
[TBL] [Abstract][Full Text] [Related]
20. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus.
Prasad GA; Wang KK; Halling KC; Buttar NS; Wongkeesong LM; Zinsmeister AR; Brankley SM; Fritcher EG; Westra WM; Krishnadath KK; Lutzke LS; Borkenhagen LS
Gastroenterology; 2008 Aug; 135(2):370-9. PubMed ID: 18538141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
